Suppr超能文献

少突胶质细胞瘤中1p/19q杂合性缺失及Sox17表达的临床意义

Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.

作者信息

Li Junzhi, Miao Na, Liu Ming, Cui Wenli, Liu Xia, Li Xinxia, Shi Xiaoli, Qing Song, Ma Yuqing, Zhang Wei, Biekemituofu Hadeti

机构信息

Department of Pathology, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uyger Automatic Region, Urumqi 830054, China.

出版信息

Int J Clin Exp Pathol. 2014 Dec 1;7(12):8609-15. eCollection 2014.

Abstract

OBJECTIVE

To study chromosome 1p/19q loss of heterozygosity (LOH) and Sox17 protein expression in oligodendrogliomas and correlate this loss with clinicopathological features.

METHODS

This study included 100 cases of oligodendrogliomas at the First Affiliated Hospital of Xinjiang Medical University from 2003 to 2014. The cases included paraffin-embedded tissues from 50 low-grade oligodendrogliomas and 50 anaplastic oligodendrogliomas. Chromosome 1p/19q LOH was detected by fluorescence in situ hybridization (FISH) and Sox17 protein expression was analyzed by immunohistochemistry. Clinicopathological characteristics of the oligodendrogliomas were compared and prognosis analyzed using Cox regression and Kaplan-Meier analyses.

RESULTS

The LOH positivity rate of 1p/19q was 52% in 50 cases of low-grade oligodendrogliomas and 68% in 50 cases of anaplastic oligodendrogliomas (P = 0.102). The rates of Sox17 expression were significantly different in oligodendrogliomas (82%) and anaplastic oligodendrogliomas (62%, P = 0.026). Single factor analysis determined that 1p/19q LOH (P = 0.000), Sox17 protein expression (P = 0.000), location (P = 0.001), chemotherapy (P = 0.000), and radiation therapy (P = 0.001) were associated with oligodendroglioma patient prognosis. Cox multiple factors regression analysis determined that 1p/19q LOH and Sox17 expression were independent prognostic factors of oligodendrogliomas.

CONCLUSION

In this study, oligodendroglioma patients with 1p/19q LOH and Sox17 protein expression had a better prognosis. Thus, analysis of 1p/19q LOH and Sox17 protein expression could significantly enhance diagnostic accuracy, guide treatment, and improve the prognosis.

摘要

目的

研究少突胶质细胞瘤中1号染色体短臂/19号染色体长臂杂合性缺失(LOH)及Sox17蛋白表达情况,并将这种缺失与临床病理特征相关联。

方法

本研究纳入了2003年至2014年新疆医科大学第一附属医院的100例少突胶质细胞瘤病例。这些病例包括50例低级别少突胶质细胞瘤和50例间变性少突胶质细胞瘤的石蜡包埋组织。采用荧光原位杂交(FISH)检测1号染色体短臂/19号染色体长臂LOH,采用免疫组织化学分析Sox17蛋白表达。比较少突胶质细胞瘤的临床病理特征,并使用Cox回归和Kaplan-Meier分析进行预后分析。

结果

50例低级别少突胶质细胞瘤中1号染色体短臂/19号染色体长臂LOH阳性率为52%,50例间变性少突胶质细胞瘤中为68%(P = 0.102)。少突胶质细胞瘤(82%)和间变性少突胶质细胞瘤(62%,P = 0.026)中Sox17表达率有显著差异。单因素分析确定1号染色体短臂/19号染色体长臂LOH(P = 0.000)、Sox17蛋白表达(P = 0.000)、位置(P = 0.001)、化疗(P = 0.000)和放疗(P = 0.001)与少突胶质细胞瘤患者预后相关。Cox多因素回归分析确定1号染色体短臂/19号染色体长臂LOH和Sox17表达是少突胶质细胞瘤的独立预后因素。

结论

在本研究中,1号染色体短臂/19号染色体长臂LOH及Sox17蛋白表达的少突胶质细胞瘤患者预后较好。因此,分析1号染色体短臂/19号染色体长臂LOH及Sox17蛋白表达可显著提高诊断准确性、指导治疗并改善预后。

相似文献

5
The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
J Clin Neurosci. 2011 Mar;18(3):329-33. doi: 10.1016/j.jocn.2010.07.101. Epub 2011 Jan 17.
8
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
Acta Neuropathol. 2002 Mar;103(3):267-75. doi: 10.1007/s004010100464. Epub 2001 Nov 22.
10
Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Cancer Genet Cytogenet. 2009 Oct;194(1):12-22. doi: 10.1016/j.cancergencyto.2009.05.004.

引用本文的文献

1
SOX17 expression in ovarian clear cell carcinoma.
J Ovarian Res. 2024 Nov 11;17(1):221. doi: 10.1186/s13048-024-01549-3.
3
Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
Tumour Biol. 2015 Sep;36(10):8025-34. doi: 10.1007/s13277-015-3547-3. Epub 2015 May 14.

本文引用的文献

4
Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.
5
Wnt/β-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells.
Anat Rec (Hoboken). 2012 Dec;295(12):2104-13. doi: 10.1002/ar.22592. Epub 2012 Sep 14.
7
SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma.
Epigenetics. 2010 Nov-Dec;5(8):743-9. doi: 10.4161/epi.5.8.13104. Epub 2010 Nov 22.
8
Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Breast Cancer Res Treat. 2010 Feb;119(3):601-12. doi: 10.1007/s10549-009-0339-8. Epub 2009 Mar 20.
9
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer.
Cancer Res. 2008 Apr 15;68(8):2764-72. doi: 10.1158/0008-5472.CAN-07-6349.
10
The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007 Aug;114(2):97-109. doi: 10.1007/s00401-007-0243-4. Epub 2007 Jul 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验